Aandeel Pharming Group (PHARM)

Profiel:

Bedrijf:              Pharming Group N.V.
Symbool:          PHARM
ISIN:                  NL0010391025
Beurs:               Euronext Amsterdam
Sector:              Biotechnologie

Beoordeling:    Bekijk met Premium 
Risico:              Bekijk met Premium

Cijfers:

Marktkapitalisatie:                       
Uitstaande aandelen:                  

Vorige slot:                                   
Open:                                             
Hoog:                                            
Laag:                                             
Dag range:                                     
Volume:                                         

Nieuws 

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost…

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that new clinical data for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, an investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be presented by V. Koneti Rao, MD, FRCPA, staff physician in the Primary Immune Deficiency Clinic at the National Institute of Health in Bethesda, Maryl

Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

03 Nov, 2022 06:00 Yahoo! Finance

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference in London, November 15-17, 2022.

02 Nov, 2022 06:00 Yahoo! Finance

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that its Chief Financial Officer, Jeroen Wakkerman, will present at the Stifel Healthcare Conference in New York, November 15-16, 2022.

Investors in Pharming Group N.V. ( AMS:PHARM ) had a good week, as its shares rose 2.2% to close at €0.98 following the…

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The application, submitted earlier in October 2022, is for the investigational drug, leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022.

18 Oct, 2022 13:40 Yahoo! Finance

Here is how Lantheus Holdings (LNTH) and Pharming Group N.V. Sponsored ADR (PHAR) have performed compared to their sector so far this year.

12 Oct, 2022 05:00 Yahoo! Finance

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce financial results for the nine months ended September 30, 2022 on Thursday, October 27, 2022.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents 12 years or older.

The FDA has accepted Pharming Group NV’s (NASDAQ: PHAR) marketing application seeking approval for leniolisib for rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification. Submitted by Pharming on July 29, 2022, the application was supported by positive data from a Phase 2/3 study of leniolisib, which me

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. The FDA has assigned a Prescription

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that a new diagnosis code for reporting cases of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be added to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) by the US Centers for Disease Control and Prevention (CDC). The diagnosis code, D81.82 ‒ Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib. Leniolisib has been studied for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents age 12 or older in the European Economic Area (EEA

25 Jul, 2022 05:00 Yahoo! Finance

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM)/(Nasdaq: PHAR) confirms it will announce financial results for the six months ended 30 June 2022 on Thursday, August 4, 2022.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference 2022, a hybrid meeting based in New York, at 22:00-22:30 CET/16:00-16:30 EDT on 9 June 2022.